FDA
-
-
-
-
-
-
-
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
-
-
-
-
-
-
-
Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Bioventus (BVS) Receives FDA 510(k) Clearance for SonaStar Elite
-
-
-
-
-
-
-
Bioventus TheraSkin Coverage Expands to Provide for 17 Million More Covered Lives
-
-
-
-
-
-
-
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
-
-
-
-
-
-
-
Bioventus Announces Chief Financial Officer Transition Plan
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

